A new risk score for patients after first recurrence of stage 4 neuroblastoma aged ≥18 months at first diagnosis

BACKGROUND: The prognosis of patients with recurrences from stage 4 neuroblastoma is not uniformly dismal. The evaluation of new therapies therefore needs to consider the individual risks of the treated patients. This study aims to define clinically useful risk criteria. PATIENTS AND METHODS: Inclus...

Descripción completa

Detalles Bibliográficos
Autores principales: Kreitz, Kiana, Ernst, Angela, Schmidt, René, Simon, Thorsten, Fischer, Matthias, Volland, Ruth, Hero, Barbara, Berthold, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6885891/
https://www.ncbi.nlm.nih.gov/pubmed/31631570
http://dx.doi.org/10.1002/cam4.2562

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6885891/
https://www.ncbi.nlm.nih.gov/pubmed/31631570
http://dx.doi.org/10.1002/cam4.2562

Ejemplares similares